0000899243-18-016599.txt : 20180614
0000899243-18-016599.hdr.sgml : 20180614
20180614160841
ACCESSION NUMBER: 0000899243-18-016599
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180613
FILED AS OF DATE: 20180614
DATE AS OF CHANGE: 20180614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BJERKHOLT ERIC
CENTRAL INDEX KEY: 0001197350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 18899253
MAIL ADDRESS:
STREET 1: 132 PURDURE AVENUE
CITY: KENGSINGTON
STATE: CA
ZIP: 94708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-13
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001197350
BJERKHOLT ERIC
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
Chief Financial Officer
Common Stock, $0.0001 par value
2018-06-13
4
P
0
1600
30.4144
A
19485
D
The transaction was executed in multiple trades in prices ranging from $30.35 to $30.4292, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
Includes shares represented by restricted stock units ("RSUs") and will be settled in common stock upon vesting over a specified time, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 385 shares acquired on May 15, 2018 pursuant to Issuer's employee stock purchase plan.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Eric H. Bjerkholt
2018-06-14